Nerve growth factor levels in parkinson disease and experimental parkinsonian rats
Nerve growth factor (NGF) is well established for its ability to promote growth and survival for specific neuronal populations. However, its participation in the pathogenesis of human nervous system disorders such as Parkinson’s disease (PD) remains to be resolved. This study examined NGF levels in...
Gespeichert in:
| Veröffentlicht in: | Brain research 2002-10, Vol.952 (1), p.122-127 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 127 |
|---|---|
| container_issue | 1 |
| container_start_page | 122 |
| container_title | Brain research |
| container_volume | 952 |
| creator | Lorigados Pedre, Lourdes Pavón Fuentes, Nancy Alvarez González, Lázaro McRae, Amanda Serrano Sánchez, Teresa Blanco Lescano, Lissette Macı́as González, Raúl |
| description | Nerve growth factor (NGF) is well established for its ability to promote growth and survival for specific neuronal populations. However, its participation in the pathogenesis of human nervous system disorders such as Parkinson’s disease (PD) remains to be resolved. This study examined NGF levels in the serum of healthy persons, in patients with PD and in parkinsonian rats using a double site immune-enzymatic assay (EIA) with the murine 27/21 anti-beta-NGF monoclonal antibody. PD patients were divided in two groups according to the stages of the disease (Grade: I–II and Grade: III–IV of Hoenh and Yahr scale). NGF levels in parkinsonian rats showed significant (
P |
| doi_str_mv | 10.1016/S0006-8993(02)03222-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_18595075</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006899302032225</els_id><sourcerecordid>18595075</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-ee1cd79f22a3b11e2f4f9b566681f3e9f8358f996185e5be38ebc2d33cce0a113</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EoqXwCSBvQLAI-BEn8QqhipeEQOKxthxnDIbUKXZa4O9J24guWY1GOnfm6iC0T8kpJTQ7eyKEZEkhJT8m7IRwxlgiNtCQFjlLMpaSTTT8QwZoJ8b3buVckm00oIxnPKV0iB7vIcwBv4bmq33DVpu2CbiGOdQRO4-nOnw4HxuPKxdBR8DaVxi-pxDcBHyr6zXitMdBt3EXbVldR9jr5wi9XF0-j2-Su4fr2_HFXWLSPG0TAGqqXFrGNC8pBWZTK0uRZVlBLQdpCy4KK2VGCwGiBF5AaVjFuTFANKV8hI5Wd6eh-ZxBbNXERQN1rT00s6i6nBQkFx0oVqAJTYwBrJp27XX4UZSohUy1lKkWphRhailTLXIH_YNZOYFqnertdcBhD-hodG2D9sbFNcdlSlORdtz5iuuswtxBUNE48AYqF8C0qmrcP1V-Afttkd4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18595075</pqid></control><display><type>article</type><title>Nerve growth factor levels in parkinson disease and experimental parkinsonian rats</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lorigados Pedre, Lourdes ; Pavón Fuentes, Nancy ; Alvarez González, Lázaro ; McRae, Amanda ; Serrano Sánchez, Teresa ; Blanco Lescano, Lissette ; Macı́as González, Raúl</creator><creatorcontrib>Lorigados Pedre, Lourdes ; Pavón Fuentes, Nancy ; Alvarez González, Lázaro ; McRae, Amanda ; Serrano Sánchez, Teresa ; Blanco Lescano, Lissette ; Macı́as González, Raúl</creatorcontrib><description>Nerve growth factor (NGF) is well established for its ability to promote growth and survival for specific neuronal populations. However, its participation in the pathogenesis of human nervous system disorders such as Parkinson’s disease (PD) remains to be resolved. This study examined NGF levels in the serum of healthy persons, in patients with PD and in parkinsonian rats using a double site immune-enzymatic assay (EIA) with the murine 27/21 anti-beta-NGF monoclonal antibody. PD patients were divided in two groups according to the stages of the disease (Grade: I–II and Grade: III–IV of Hoenh and Yahr scale). NGF levels in parkinsonian rats showed significant (
P<0.01) reductions when compared with serum from normal animals. The NGF levels in early states of the disease (Grade I–II) showed greater reductions (
P<0.01) in comparison to those with advanced stages (Grade III–IV). We consider that alterations in NGF levels may reflect ongoing neurodegenerative processes in PD.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/S0006-8993(02)03222-5</identifier><identifier>PMID: 12363411</identifier><identifier>CODEN: BRREAP</identifier><language>eng</language><publisher>London: Elsevier B.V</publisher><subject>Adult ; Animals ; Biological and medical sciences ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Disease Models, Animal ; Enzyme immunoassay ; Humans ; Immunoenzyme Techniques - methods ; Medical sciences ; Middle Aged ; Nerve Growth Factor - blood ; Neurology ; NGF ; Oxidopamine ; Parkinson Disease - blood ; Parkinsonian Disorders - blood ; Parkinsonian Disorders - chemically induced ; Parkinson’s disease ; Rats ; Serum ; Sympatholytics</subject><ispartof>Brain research, 2002-10, Vol.952 (1), p.122-127</ispartof><rights>2002 Elsevier Science B.V.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-ee1cd79f22a3b11e2f4f9b566681f3e9f8358f996185e5be38ebc2d33cce0a113</citedby><cites>FETCH-LOGICAL-c474t-ee1cd79f22a3b11e2f4f9b566681f3e9f8358f996185e5be38ebc2d33cce0a113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006899302032225$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13941454$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12363411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lorigados Pedre, Lourdes</creatorcontrib><creatorcontrib>Pavón Fuentes, Nancy</creatorcontrib><creatorcontrib>Alvarez González, Lázaro</creatorcontrib><creatorcontrib>McRae, Amanda</creatorcontrib><creatorcontrib>Serrano Sánchez, Teresa</creatorcontrib><creatorcontrib>Blanco Lescano, Lissette</creatorcontrib><creatorcontrib>Macı́as González, Raúl</creatorcontrib><title>Nerve growth factor levels in parkinson disease and experimental parkinsonian rats</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>Nerve growth factor (NGF) is well established for its ability to promote growth and survival for specific neuronal populations. However, its participation in the pathogenesis of human nervous system disorders such as Parkinson’s disease (PD) remains to be resolved. This study examined NGF levels in the serum of healthy persons, in patients with PD and in parkinsonian rats using a double site immune-enzymatic assay (EIA) with the murine 27/21 anti-beta-NGF monoclonal antibody. PD patients were divided in two groups according to the stages of the disease (Grade: I–II and Grade: III–IV of Hoenh and Yahr scale). NGF levels in parkinsonian rats showed significant (
P<0.01) reductions when compared with serum from normal animals. The NGF levels in early states of the disease (Grade I–II) showed greater reductions (
P<0.01) in comparison to those with advanced stages (Grade III–IV). We consider that alterations in NGF levels may reflect ongoing neurodegenerative processes in PD.</description><subject>Adult</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Disease Models, Animal</subject><subject>Enzyme immunoassay</subject><subject>Humans</subject><subject>Immunoenzyme Techniques - methods</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nerve Growth Factor - blood</subject><subject>Neurology</subject><subject>NGF</subject><subject>Oxidopamine</subject><subject>Parkinson Disease - blood</subject><subject>Parkinsonian Disorders - blood</subject><subject>Parkinsonian Disorders - chemically induced</subject><subject>Parkinson’s disease</subject><subject>Rats</subject><subject>Serum</subject><subject>Sympatholytics</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EoqXwCSBvQLAI-BEn8QqhipeEQOKxthxnDIbUKXZa4O9J24guWY1GOnfm6iC0T8kpJTQ7eyKEZEkhJT8m7IRwxlgiNtCQFjlLMpaSTTT8QwZoJ8b3buVckm00oIxnPKV0iB7vIcwBv4bmq33DVpu2CbiGOdQRO4-nOnw4HxuPKxdBR8DaVxi-pxDcBHyr6zXitMdBt3EXbVldR9jr5wi9XF0-j2-Su4fr2_HFXWLSPG0TAGqqXFrGNC8pBWZTK0uRZVlBLQdpCy4KK2VGCwGiBF5AaVjFuTFANKV8hI5Wd6eh-ZxBbNXERQN1rT00s6i6nBQkFx0oVqAJTYwBrJp27XX4UZSohUy1lKkWphRhailTLXIH_YNZOYFqnertdcBhD-hodG2D9sbFNcdlSlORdtz5iuuswtxBUNE48AYqF8C0qmrcP1V-Afttkd4</recordid><startdate>20021011</startdate><enddate>20021011</enddate><creator>Lorigados Pedre, Lourdes</creator><creator>Pavón Fuentes, Nancy</creator><creator>Alvarez González, Lázaro</creator><creator>McRae, Amanda</creator><creator>Serrano Sánchez, Teresa</creator><creator>Blanco Lescano, Lissette</creator><creator>Macı́as González, Raúl</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20021011</creationdate><title>Nerve growth factor levels in parkinson disease and experimental parkinsonian rats</title><author>Lorigados Pedre, Lourdes ; Pavón Fuentes, Nancy ; Alvarez González, Lázaro ; McRae, Amanda ; Serrano Sánchez, Teresa ; Blanco Lescano, Lissette ; Macı́as González, Raúl</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-ee1cd79f22a3b11e2f4f9b566681f3e9f8358f996185e5be38ebc2d33cce0a113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Disease Models, Animal</topic><topic>Enzyme immunoassay</topic><topic>Humans</topic><topic>Immunoenzyme Techniques - methods</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nerve Growth Factor - blood</topic><topic>Neurology</topic><topic>NGF</topic><topic>Oxidopamine</topic><topic>Parkinson Disease - blood</topic><topic>Parkinsonian Disorders - blood</topic><topic>Parkinsonian Disorders - chemically induced</topic><topic>Parkinson’s disease</topic><topic>Rats</topic><topic>Serum</topic><topic>Sympatholytics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lorigados Pedre, Lourdes</creatorcontrib><creatorcontrib>Pavón Fuentes, Nancy</creatorcontrib><creatorcontrib>Alvarez González, Lázaro</creatorcontrib><creatorcontrib>McRae, Amanda</creatorcontrib><creatorcontrib>Serrano Sánchez, Teresa</creatorcontrib><creatorcontrib>Blanco Lescano, Lissette</creatorcontrib><creatorcontrib>Macı́as González, Raúl</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lorigados Pedre, Lourdes</au><au>Pavón Fuentes, Nancy</au><au>Alvarez González, Lázaro</au><au>McRae, Amanda</au><au>Serrano Sánchez, Teresa</au><au>Blanco Lescano, Lissette</au><au>Macı́as González, Raúl</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nerve growth factor levels in parkinson disease and experimental parkinsonian rats</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>2002-10-11</date><risdate>2002</risdate><volume>952</volume><issue>1</issue><spage>122</spage><epage>127</epage><pages>122-127</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><coden>BRREAP</coden><abstract>Nerve growth factor (NGF) is well established for its ability to promote growth and survival for specific neuronal populations. However, its participation in the pathogenesis of human nervous system disorders such as Parkinson’s disease (PD) remains to be resolved. This study examined NGF levels in the serum of healthy persons, in patients with PD and in parkinsonian rats using a double site immune-enzymatic assay (EIA) with the murine 27/21 anti-beta-NGF monoclonal antibody. PD patients were divided in two groups according to the stages of the disease (Grade: I–II and Grade: III–IV of Hoenh and Yahr scale). NGF levels in parkinsonian rats showed significant (
P<0.01) reductions when compared with serum from normal animals. The NGF levels in early states of the disease (Grade I–II) showed greater reductions (
P<0.01) in comparison to those with advanced stages (Grade III–IV). We consider that alterations in NGF levels may reflect ongoing neurodegenerative processes in PD.</abstract><cop>London</cop><cop>Amsterdam</cop><cop>New York, NY</cop><pub>Elsevier B.V</pub><pmid>12363411</pmid><doi>10.1016/S0006-8993(02)03222-5</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-8993 |
| ispartof | Brain research, 2002-10, Vol.952 (1), p.122-127 |
| issn | 0006-8993 1872-6240 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_18595075 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Animals Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Disease Models, Animal Enzyme immunoassay Humans Immunoenzyme Techniques - methods Medical sciences Middle Aged Nerve Growth Factor - blood Neurology NGF Oxidopamine Parkinson Disease - blood Parkinsonian Disorders - blood Parkinsonian Disorders - chemically induced Parkinson’s disease Rats Serum Sympatholytics |
| title | Nerve growth factor levels in parkinson disease and experimental parkinsonian rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T18%3A00%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nerve%20growth%20factor%20levels%20in%20parkinson%20disease%20and%20experimental%20parkinsonian%20rats&rft.jtitle=Brain%20research&rft.au=Lorigados%20Pedre,%20Lourdes&rft.date=2002-10-11&rft.volume=952&rft.issue=1&rft.spage=122&rft.epage=127&rft.pages=122-127&rft.issn=0006-8993&rft.eissn=1872-6240&rft.coden=BRREAP&rft_id=info:doi/10.1016/S0006-8993(02)03222-5&rft_dat=%3Cproquest_cross%3E18595075%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18595075&rft_id=info:pmid/12363411&rft_els_id=S0006899302032225&rfr_iscdi=true |